{"id":105719,"date":"2023-11-09T05:13:00","date_gmt":"2023-11-09T05:13:00","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=114240"},"modified":"2023-11-09T05:13:00","modified_gmt":"2023-11-09T05:13:00","slug":"nyxoah-reports-third-quarter-2023-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/kuwaitnewsgazette.com\/nyxoah-reports-third-quarter-2023-financial-and-operating-results\/","title":{"rendered":"Nyxoah Reports Third Quarter 2023 Financial and Operating Results"},"content":{"rendered":"
Nyxoah Reports Third Quarter 2023 Financial and Operating Results<\/strong> Mont-Saint-Guibert, Belgium \u2013 November 8, 2023 10:05pm CET \/ 4:05pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong> (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the third quarter of 2023.<\/p>\n Recent Financial and Operating Highlights<\/strong><\/p>\n \u201cNyxoah is entering one of the most exciting times in the company\u2019s history. We will report data from our DREAM U.S. pivotal trial early next year, shortly thereafter complete our modular PMA submission, and expect FDA approval late 2024,\u201d commented Olivier Taelman, Chief Executive Officer. \u201cHypoglossal nerve stimulation (HGNS) remains highly underpenetrated and guiding patients through their OSA journey is key to unlocking the market\u2019s potential. Our agreement with ResMed Germany, which takes ResMed from a valued investor to commercial partner, creates a continuum of care that directs patients towards the appropriate treatment, resulting in greater therapy penetration.\u201d<\/p>\n CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS\u00a0(unaudited)<\/strong>
\nPartners with ResMed Germany to increase OSA awareness and therapy penetration<\/em><\/p>\n\n
\n\u00a0(in thousands)<\/strong><\/p>\n